Table 1.
Patient Characteristics
| Characteristics | Total | Standard Dose | High Dose | |
|---|---|---|---|---|
| Sex | P = .5461 | |||
| Female | 76 (42.2%) | 36 (40.0%) | 40 (44.4%) | |
| Male | 104 (57.8%) | 54 (60.0%) | 50 (55.6%) | |
| Age at inclusion (n = 180) | ||||
| ≤50 years | 33 (18.3%) | 17 (18.9%) | 16 (17.8%) | |
| >50 years | 147 (81.7%) | 73 (81.1%) | 74 (82.2%) | |
| Median (range) | 61.0 (26.0–84.0) | 61.5 (33.0–83.0) | 60.5 (26.0–84.0) | P = .8472 |
| Performance status (n = 165) | P = .1015 | |||
| 0 | 92 (55.8%) | 48 (59.3%) | 44 (52.4%) | |
| 1 | 62 (37.6%) | 31 (38.3%) | 31 (36.9%) | |
| 2 | 11 (6.7%) | 2 (2.5%) | 9 (10.7%) | |
| Missing data | 15 | 9 | 6 | |
| Tumor size at diagnosis (mm) (n = 115) | P = .0703 | |||
| Median | 33.0 | 35.0 | 30.0 | |
| (Range) | (3.0–95.0) | (3.0–95.0) | (6.0–62.0) | |
| Missing data | 65 (36.11%) | 31 (34.4%) | 34 (37.7%) | |
| Type of surgery (n = 180) | P = .8347 | |||
| Biopsy | 27 (15.0%) | 14 (15.6%) | 13 (14.4%) | |
| Surgical resection | 153 (85.0%) | 76 (84.4%) | 77 (85.6%) | |
| MGMT promoter methylation (N = 180) | P = .8815 | |||
| Unmethylated | 91 (50.6%) | 45 (50.0%) | 46 (51.1%) | |
| Methylated | 89 (49.4%) | 45 (50.0%) | 44 (48.9%) | |
| IDH status (n = 113) | P = .7060 | |||
| Wild type | 108 (95.5%) | 56 (94.9%) | 52 (96%) | |
| Mutated | 5 (4.4%) | 3 (5%) | 2 (3.7%) | |
| Not performed | 67 (37.2%) | 31 (34.4%) | 36 (40%) |